Cumulative evidence suggests that cholinesterase inhibitors (AChE and BChE) can improve cholinergic transmission by blocking the degradation of choline, therefore, serving as a strategy for alleviating the symptoms of AD in patients (Moreta et al., 2021). The gene discussed is ACHE; the disease is Alzheimer disease.